833 related articles for article (PubMed ID: 25908823)
1. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
[TBL] [Abstract][Full Text] [Related]
2. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW; Gibson DA; DiAntonio A; Milbrandt J
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6271-E6280. PubMed ID: 27671644
[TBL] [Abstract][Full Text] [Related]
3. SARM1 is a metabolic sensor activated by an increased NMN/NAD
Figley MD; Gu W; Nanson JD; Shi Y; Sasaki Y; Cunnea K; Malde AK; Jia X; Luo Z; Saikot FK; Mosaiab T; Masic V; Holt S; Hartley-Tassell L; McGuinness HY; Manik MK; Bosanac T; Landsberg MJ; Kerry PS; Mobli M; Hughes RO; Milbrandt J; Kobe B; DiAntonio A; Ve T
Neuron; 2021 Apr; 109(7):1118-1136.e11. PubMed ID: 33657413
[TBL] [Abstract][Full Text] [Related]
4. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.
Gerdts J; Summers DW; Milbrandt J; DiAntonio A
Neuron; 2016 Feb; 89(3):449-60. PubMed ID: 26844829
[TBL] [Abstract][Full Text] [Related]
5. The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
Garb J; Amitai G; Lu A; Ofir G; Brandis A; Mehlman T; Kranzusch PJ; Sorek R
PLoS One; 2024; 19(4):e0302251. PubMed ID: 38635746
[TBL] [Abstract][Full Text] [Related]
6. The chemical biology of NAD
Icso JD; Thompson PR
Curr Opin Chem Biol; 2022 Aug; 69():102176. PubMed ID: 35780654
[TBL] [Abstract][Full Text] [Related]
7. NAD
Horsefield S; Burdett H; Zhang X; Manik MK; Shi Y; Chen J; Qi T; Gilley J; Lai JS; Rank MX; Casey LW; Gu W; Ericsson DJ; Foley G; Hughes RO; Bosanac T; von Itzstein M; Rathjen JP; Nanson JD; Boden M; Dry IB; Williams SJ; Staskawicz BJ; Coleman MP; Ve T; Dodds PN; Kobe B
Science; 2019 Aug; 365(6455):793-799. PubMed ID: 31439792
[TBL] [Abstract][Full Text] [Related]
8. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD
Sasaki Y; Nakagawa T; Mao X; DiAntonio A; Milbrandt J
Elife; 2016 Oct; 5():. PubMed ID: 27735788
[TBL] [Abstract][Full Text] [Related]
9. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD
Essuman K; Summers DW; Sasaki Y; Mao X; DiAntonio A; Milbrandt J
Neuron; 2017 Mar; 93(6):1334-1343.e5. PubMed ID: 28334607
[TBL] [Abstract][Full Text] [Related]
10. Multiple domain interfaces mediate SARM1 autoinhibition.
Shen C; Vohra M; Zhang P; Mao X; Figley MD; Zhu J; Sasaki Y; Wu H; DiAntonio A; Milbrandt J
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468661
[TBL] [Abstract][Full Text] [Related]
11. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.
White MA; Lin Z; Kim E; Henstridge CM; Pena Altamira E; Hunt CK; Burchill E; Callaghan I; Loreto A; Brown-Wright H; Mead R; Simmons C; Cash D; Coleman MP; Sreedharan J
Acta Neuropathol Commun; 2019 Oct; 7(1):166. PubMed ID: 31661035
[TBL] [Abstract][Full Text] [Related]
12. Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.
Loring HS; Thompson PR
Cell Chem Biol; 2020 Jan; 27(1):1-13. PubMed ID: 31761689
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.
Loreto A; Hill CS; Hewitt VL; Orsomando G; Angeletti C; Gilley J; Lucci C; Sanchez-Martinez A; Whitworth AJ; Conforti L; Dajas-Bailador F; Coleman MP
Neurobiol Dis; 2020 Feb; 134():104678. PubMed ID: 31740269
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.
Sasaki Y; Zhu J; Shi Y; Gu W; Kobe B; Ve T; DiAntonio A; Milbrandt J
Exp Neurol; 2021 Nov; 345():113842. PubMed ID: 34403688
[TBL] [Abstract][Full Text] [Related]
15. The NAD
Jiang Y; Liu T; Lee CH; Chang Q; Yang J; Zhang Z
Nature; 2020 Dec; 588(7839):658-663. PubMed ID: 33053563
[TBL] [Abstract][Full Text] [Related]
16. Sarm1 Deletion, but Not Wld
Gilley J; Ribchester RR; Coleman MP
Cell Rep; 2017 Oct; 21(1):10-16. PubMed ID: 28978465
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.
Wu T; Zhu J; Strickland A; Ko KW; Sasaki Y; Dingwall CB; Yamada Y; Figley MD; Mao X; Neiner A; Bloom AJ; DiAntonio A; Milbrandt J
Cell Rep; 2021 Oct; 37(3):109872. PubMed ID: 34686345
[TBL] [Abstract][Full Text] [Related]
18. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
19. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.
Sasaki Y; Engber TM; Hughes RO; Figley MD; Wu T; Bosanac T; Devraj R; Milbrandt J; Krauss R; DiAntonio A
Exp Neurol; 2020 Jul; 329():113252. PubMed ID: 32087251
[TBL] [Abstract][Full Text] [Related]
20. The SARM1 axon degeneration pathway: control of the NAD
Figley MD; DiAntonio A
Curr Opin Neurobiol; 2020 Aug; 63():59-66. PubMed ID: 32311648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
